Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study
ConclusionAlthough surreptitious metformin use impacted the primary analysis, reductions in blood glucose and body weight were observed with ertugliflozin in patients with T2DM and stage 3 CKD; ertugliflozin had an acceptable safety profile.FundingMerck Sharp& Dohme Corp. a subsidiary of Merck& Co., Inc., Kenilworth, NJ, USA and Pfizer Inc.Trial RegistrationClinicaltrials.gov identifier NCT01986855.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
More News: Chronic Kidney Disease | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Fortamet | Insulin | Merck | Metformin | Pfizer | Sodium | Study | Urinary Tract Infections | Urology & Nephrology